{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:11:03Z","timestamp":1790655063340,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-15-RHUS-0004"],"award-info":[{"award-number":["ANR-15-RHUS-0004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-74934-z","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:01:58Z","timestamp":1728864118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Benefit of combination therapy with dapagliflozin and eplerenone on cardiac function and fibrosis in rats with non-diabetic chronic kidney disease"],"prefix":"10.1038","volume":"14","author":[{"given":"M.","family":"Souli\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Lima-Posada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Palacios-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Lopez-Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"74934_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jacc.2012.01.077","volume":"60","author":"C Ronco","year":"2012","unstructured":"Ronco, C., Cicoira, M. & McCullough, P. A. Cardiorenal syndrome type 1: Pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J. Am. Coll. Cardiol. 60, 1031\u20131042 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"74934_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000349972","volume":"182","author":"JA Tumlin","year":"2013","unstructured":"Tumlin, J. A. et al. Cardiorenal syndrome type 4: Insights on clinical presentation and pathophysiology from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib. Nephrol. 182, 158\u2013173 (2013).","journal-title":"Contrib. Nephrol."},{"key":"74934_CR3","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1093\/eurheartj\/ehs205","volume":"33","author":"M Metra","year":"2012","unstructured":"Metra, M., Cotter, G., Gheorghiade, M., Dei Cas, L. & Voors, A. A. The role of the kidney in heart failure. Eur. Heart J. 33, 2135\u20132142 (2012).","journal-title":"Eur. Heart J."},{"key":"74934_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cardfail.2007.03.011","volume":"13","author":"JT Heywood","year":"2007","unstructured":"Heywood, J. T. et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database. J. Card. Fail. 13, 422\u2013430 (2007).","journal-title":"J. Card. Fail."},{"key":"74934_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"key":"74934_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus, J. A. et al. The SGLT2 inhibitor canagliflozin in heart failure: The CHIEF-HF remote, patient-centered randomized trial. Nat. Med. 28, 809\u2013813 (2022).","journal-title":"Nat. Med."},{"key":"74934_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"key":"74934_CR8","first-page":"1700","volume":"35","author":"DC Wheeler","year":"2020","unstructured":"Wheeler, D. C. et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: Baseline characteristics. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc. 35, 1700\u20131711 (2020).","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"74934_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/1742-2094-9-260","volume":"9","author":"B Chantong","year":"2012","unstructured":"Chantong, B., Kratschmar, D. V., Nashev, L. G., Balazs, Z. & Odermatt, A. Mineralocorticoid and glucocorticoid receptors differentially regulate NF-kappaB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells. J. Neuroinflammation 9, 260 (2012).","journal-title":"J. Neuroinflammation"},{"key":"74934_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/ddr.21760","volume":"82","author":"V Patel","year":"2021","unstructured":"Patel, V., Joharapurkar, A. & Jain, M. Role of mineralocorticoid receptor antagonists in kidney diseases. Drug Dev. Res. 82, 341\u2013363 (2021).","journal-title":"Drug Dev. Res."},{"key":"74934_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000503712","volume":"50","author":"LM Ruilope","year":"2019","unstructured":"Ruilope, L. M. et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am. J. Nephrol. 50, 345\u2013356 (2019).","journal-title":"Am. J. Nephrol."},{"key":"74934_CR12","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219\u20132229 (2020).","journal-title":"N. Engl. J. Med."},{"key":"74934_CR13","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252\u20132263 (2021).","journal-title":"N. Engl. J. Med."},{"key":"74934_CR14","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","volume":"33","author":"M Provenzano","year":"2022","unstructured":"Provenzano, M. et al. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: A randomized crossover clinical trial. J. Am. Soc. Nephrol. JASN 33, 1569\u20131580 (2022).","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"74934_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.yjmcc.2011.05.012","volume":"51","author":"Y Fang","year":"2011","unstructured":"Fang, Y. et al. Improvement of left ventricular diastolic function induced by \u03b2-blockade: A comparison between nebivolol and metoprolol. J. Mol. Cell. Cardiol. 51, 168\u2013176 (2011).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"74934_CR16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1161\/01.CIR.58.6.1072","volume":"58","author":"DJ Sahn","year":"1978","unstructured":"Sahn, D. J., DeMaria, A., Kisslo, J. & Weyman, A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 58, 1072\u20131083 (1978).","journal-title":"Circulation"},{"key":"74934_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1023\/A:1010603217785","volume":"17","author":"C Waller","year":"2001","unstructured":"Waller, C. et al. Myocardial perfusion imaging using a non-contrast agent MR imaging technique. Int. J. Cardiovasc. Imaging 17, 123\u2013132 (2001).","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"74934_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/10976640009146565","volume":"2","author":"M Nahrendorf","year":"2000","unstructured":"Nahrendorf, M. et al. In vivo assessment of cardiac remodeling after myocardial infarction in rats by cine-magnetic resonance imaging. J. Cardiovasc. Magn. Reson. 2, 171\u2013180 (2000).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"74934_CR19","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1161\/CIRCULATIONAHA.115.020143","volume":"133","author":"O Henri","year":"2016","unstructured":"Henri, O. et al. Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction. Circulation 133, 1484\u20131497 (2016).","journal-title":"Circulation"},{"key":"74934_CR20","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.3390\/ijms24032536","volume":"24","author":"I Lima-Posada","year":"2023","unstructured":"Lima-Posada, I. et al. Benefits of the non-steroidal mineralocorticoid receptor antagonist finerenone in metabolic syndrome-related heart failure with preserved ejection fraction. Int. J. Mol. Sci. 24, 2536 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"74934_CR21","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/biomedicines10102509","volume":"10","author":"S Hojn\u00e1","year":"2022","unstructured":"Hojn\u00e1, S. et al. Empagliflozin is not renoprotective in non-diabetic rat models of chronic kidney disease. Biomedicines 10, 2509 (2022).","journal-title":"Biomedicines"},{"key":"74934_CR22","doi-asserted-by":"publisher","first-page":"F692","DOI":"10.1152\/ajprenal.00053.2022","volume":"322","author":"O Kravtsova","year":"2022","unstructured":"Kravtsova, O. et al. SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats. Am. J. Physiol. Renal Physiol. 322, F692\u2013F707 (2022).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"74934_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler, D. C. et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: A prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 9, 22\u201331 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"74934_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.pop.2020.08.004","volume":"47","author":"R Bonner","year":"2020","unstructured":"Bonner, R., Albajrami, O., Hudspeth, J. & Upadhyay, A. Diabetic kidney disease. Prim. Care 47, 645\u2013659 (2020).","journal-title":"Prim. Care"},{"key":"74934_CR25","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jfma.2018.02.007","volume":"117","author":"Y-C Lin","year":"2018","unstructured":"Lin, Y.-C., Chang, Y.-H., Yang, S.-Y., Wu, K.-D. & Chu, T.-S. Update of pathophysiology and management of diabetic kidney disease. J. Formos. Med. Assoc. Taiwan Yi ZhiBold\">117, 662\u2013675 (2018).","journal-title":"J. Formos. Med. Assoc. Taiwan Yi Zhi"},{"key":"74934_CR26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407107","author":"SD Solomon","year":"2024","unstructured":"Solomon, S. D. et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med.https:\/\/doi.org\/10.1056\/NEJMoa2407107 (2024).","journal-title":"N. Engl. J. Med."},{"key":"74934_CR27","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/s41598-020-58393-w","volume":"10","author":"M Hamzaoui","year":"2020","unstructured":"Hamzaoui, M. et al. 5\/6 nephrectomy induces different renal, cardiac and vascular consequences in 129\/Sv and C57BL\/6JRj mice. Sci. Rep. 10, 1524 (2020).","journal-title":"Sci. Rep."},{"key":"74934_CR28","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1002\/jcsm.12968","volume":"13","author":"V Adams","year":"2022","unstructured":"Adams, V. et al. Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility. J. Cachexia Sarcopenia Muscle 13, 1565\u20131581 (2022).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"74934_CR29","doi-asserted-by":"publisher","first-page":"10989","DOI":"10.3390\/ijms231910989","volume":"23","author":"EB Winzer","year":"2022","unstructured":"Winzer, E. B. et al. empagliflozin preserves skeletal muscle function in a HFpEF rat model. Int. J. Mol. Sci. 23, 10989 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"74934_CR30","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1177\/15353702211035058","volume":"246","author":"D Chang","year":"2021","unstructured":"Chang, D. et al. Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction. Exp. Biol. Med. Maywood NJ 246, 2511\u20132521 (2021).","journal-title":"Exp. Biol. Med. Maywood NJ"},{"key":"74934_CR31","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/s41598-018-37690-5","volume":"9","author":"M S\u00e1rk\u00f6zy","year":"2019","unstructured":"S\u00e1rk\u00f6zy, M. et al. Chronic kidney disease induces left ventricular overexpression of the pro-hypertrophic microRNA-212. Sci. Rep. 9, 1302 (2019).","journal-title":"Sci. Rep."},{"key":"74934_CR32","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/ckj\/sfac146","volume":"15","author":"PB Mark","year":"2022","unstructured":"Mark, P. B. et al. Left ventricular dysfunction with preserved ejection fraction: The most common left ventricular disorder in chronic kidney disease patients. Clin. Kidney J. 15, 2186\u20132199 (2022).","journal-title":"Clin. Kidney J."},{"key":"74934_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2022.107095","volume":"146","author":"C Bruckert","year":"2022","unstructured":"Bruckert, C. et al. Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: Role of endothelial SGLT1 and 2. Vascul. Pharmacol. 146, 107095 (2022).","journal-title":"Vascul. Pharmacol."},{"key":"74934_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","volume":"18","author":"H-C Lee","year":"2019","unstructured":"Lee, H.-C. et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc. Diabetol. 18, 45 (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"74934_CR35","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1111\/dom.13393","volume":"20","author":"M Lachaux","year":"2018","unstructured":"Lachaux, M. et al. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. Diabetes Obes. Metab. 20, 2399\u20132407 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"74934_CR36","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.yjmcc.2018.06.008","volume":"121","author":"B Bonnard","year":"2018","unstructured":"Bonnard, B. et al. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. J. Mol. Cell. Cardiol. 121, 124\u2013133 (2018).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"74934_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus, W. J. & Tsch\u00f6pe, C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62, 263\u2013271 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"74934_CR38","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/eurheartj\/ehx818","volume":"39","author":"MD Nelson","year":"2018","unstructured":"Nelson, M. D., Wei, J. & Bairey Merz, C. N. Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: The chicken or the egg? Eur. Heart J. 39, 850\u2013852 (2018).","journal-title":"Eur. Heart J."},{"key":"74934_CR39","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1093\/eurheartj\/ehy531","volume":"39","author":"SJ Shah","year":"2018","unstructured":"Shah, S. J. et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur. Heart J. 39, 3439\u20133450 (2018).","journal-title":"Eur. Heart J."},{"key":"74934_CR40","unstructured":"Heward, S. J. & Widrich, J. Coronary perfusion pressure. In StatPearls (StatPearls Publishing, 2024)."},{"key":"74934_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110161","volume":"194","author":"S Tsukamoto","year":"2022","unstructured":"Tsukamoto, S. et al. Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis. Diabetes Res. Clin. Pract. 194, 110161 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"74934_CR42","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12882-019-1534-4","volume":"20","author":"C-C Wang","year":"2019","unstructured":"Wang, C.-C. et al. Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE\/RAGE axis in a chronic renal failure rat model. BMC Nephrol. 20, 351 (2019).","journal-title":"BMC Nephrol."},{"key":"74934_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032971","volume":"13","author":"I Lima Posada","year":"2024","unstructured":"Lima Posada, I. et al. Nonsteroidal mineralocorticoid receptor antagonist finerenone improves diastolic dysfunction in preclinical nondiabetic chronic kidney disease. J. Am. Heart Assoc. 13, e032971 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"74934_CR44","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/metabo13060736","volume":"13","author":"H Yanai","year":"2023","unstructured":"Yanai, H., Adachi, H., Hakoshima, M. & Katsuyama, H. Significance of endothelial dysfunction amelioration for sodium-glucose cotransporter 2 inhibitor-induced improvements in heart failure and chronic kidney disease in diabetic patients. Metabolites 13, 736 (2023).","journal-title":"Metabolites"},{"key":"74934_CR45","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof, P. et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52, 642\u2013652 (2021).","journal-title":"Am. J. Nephrol."},{"key":"74934_CR46","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","volume":"34","author":"Z Zhu","year":"2023","unstructured":"Zhu, Z. et al. Finerenone Added to RAS\/SGLT2 blockade for CKD in alport syndrome. Results of a randomized controlled trial with Col4a3\u2212\/\u2212 mice. J. Am. Soc. Nephrol. JASN 34, 1513\u20131520 (2023).","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"74934_CR47","first-page":"894","volume":"38","author":"JB Green","year":"2023","unstructured":"Green, J. B. et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc. 38, 894\u2013903 (2023).","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"74934_CR48","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41598-024-52331-w","volume":"14","author":"AA Sayour","year":"2024","unstructured":"Sayour, A. A. et al. Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: A meta-analysis. Sci. Rep. 14, 2188 (2024).","journal-title":"Sci. Rep."},{"key":"74934_CR49","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","volume":"243","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof, P. et al. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: Comparison at bench and bedside. Handb. Exp. Pharmacol. 243, 271\u2013305 (2017).","journal-title":"Handb. Exp. Pharmacol."},{"key":"74934_CR50","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett, A. H. et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2, 369\u2013384 (2014).","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74934-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74934-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74934-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T04:03:11Z","timestamp":1729137791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74934-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74934"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74934-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23955"}}